ABO exam phase-in application ends April 30

Article

Interested in becoming ABO certified? Qualifications will change at the end of the month.

The American Board of Optometry (ABO) reminds optometrists that as of April 30, qualifying for the ABO exam under the rules of the 3-year phase-in period expires.

ODs can still become board certified after the phase-in period ends. However, effective May 1, Experience in Active Clinical Practice and Fellowship in the College of Optometrists in Vision Development will no longer be accepted as part of the qualification. Requirements for Category 1 and 2 Education will remain unchanged.

To qualify under the rules of the phase-in period, candidates must complete the following:

•    Apply to become an active candidate no later than April 30.

•    Submit their post-graduate requirements for verification by the ABO no later than June 30.

•    Take the ABO Board Certification Examination no later than January 2014, date of the last exam using phase-in rules.

For more information, visit the ABO Web site at www.americanboardofoptometry.org or e-mail info@abopt.org.

Recent Videos
Dr Jamie Kuzniar discusses higher order aberrations and premium scleral lenses
Abby Gillogly Harsch, OD, FAAO, FSLS, shares a specific complex case of scleral lens fitting that she presented on at this year's GSLS.
Sherrol Reynolds, OD, FAAO, values the ophthalmic-optometric collaboration on display at the summit, running from February 14-17, 2025 in San Juan, Puerto Rico.
Katie Rachon, OD, FAAO, Dipl ABO, shares her excitement for the upcoming conference and what it means for an optometrist's toolbox.
EnVision Summit Cochair Cecelia Koetting, OD, FAAO, Dipl ABO, says that attendees should get ready for more discussion-based panels at this year's conference.
From contact lens dropout to addressing diabetic retinopathy in rural communities, optometrists choose an area of eye care research that they would expand, given the appropriate resources.
Bonnie An Henderson in an interview for the EnVision Summit
© 2025 MJH Life Sciences

All rights reserved.